RBX2660 Receives FDA Breakthrough Therapy Designation for Recurrent C. diff Infection
RBX2660, a microbiota restoration therapy developed by Rebiotix and acquired by Ferring, has been granted Breakthrough Therapy Designation by the FDA for recurrent Clostridioides difficile infection.
Ferring Expands Adstiladrin Production Capacity with New Facility in Finland
Ferring is expanding its manufacturing capabilities with a new 25,000 square meter facility in Finland to produce the drug substance for Adstiladrin.
© Copyright 2025. All Rights Reserved by MedPath